Výsledky vyhledávání - "Jeffrey E, Rubnitz"

Akademický článek

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)

KMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination.

Externí odkaz: https://doaj.org/article/2cd886b587c94bdaa2bd04fdff849913

Zobrazit plný text záznamu

Akademický článek

The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)

Paediatric therapy-related myeloid neoplasms (tMN) have a dismal prognosis and have not been comprehensively profiled. Here the authors characterise the molecular landscape of 84 paediatric tMN patients, and find that, unlike adult tMNs, these do not

Externí odkaz: https://doaj.org/article/fe707965968044aaa183257f76774e4d

Zobrazit plný text záznamu

Akademický článek

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML

Autor: Daelynn R. Buelow, Stanley B. Pounds, Yong‐Dong Wang, Lei Shi, Yongjin Li, David Finkelstein, Sheila Shurtleff, Geoffrey Neale, Hiroto Inaba, Raul C. Ribeiro, Reid Palumbo, Dominique Garrison, Shelley J. Orwick, James S. Blachly, Karl Kroll, John C. Byrd, Tanja A. Gruber, Jeffrey E. Rubnitz, Sharyn D. Baker

Publikováno v: Clinical and Translational Science, Vol 12, Iss 6, Pp 641-647 (2019)

Fms‐like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations, common in pediatric acute myeloid leukemia (AML), associate with early relapse and poor prognosis. Past studies have suggested additional cooperative mutations are requi

Externí odkaz: https://doaj.org/article/b729c098fb6e48d4859209165db95c5f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Autor: Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker

Publikováno v: Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)

Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be u

Externí odkaz: https://doaj.org/article/f909cbdab341455d9f702b6081a46e6f

Zobrazit plný text záznamu

Akademický článek

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

Autor: Rosa Nguyen, Huiyun Wu, Stanley Pounds, Hiroto Inaba, Raul C. Ribeiro, David Cullins, Barbara Rooney, Teresa Bell, Norman J. Lacayo, Kenneth Heym, Barbara Degar, Deborah Schiff, William E. Janssen, Brandon Triplett, Ching-Hon Pui, Wing Leung, Jeffrey E. Rubnitz

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)

Abstract Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural kille

Externí odkaz: https://doaj.org/article/4196b54e9163489ba534ba9dc6b66a38

Zobrazit plný text záznamu

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(16), 2963-2974. American Society of Clinical Oncology
van Weelderen, R E, Klein, K, Harrison, C J, Jiang, Y, Abrahamsson, J, Arad-Cohen, N, Bart-Delabesse, E, Buldini, B, de Moerloose, B, Dworzak, M N, Elitzur, S, Fernández Navarro, J M, Gerbing, R B, Goemans, B F, de Groot-Kruseman, H A, Guest, E, Ha, S-Y, Hasle, H, Kelaidi, C, Lapillonne, H L, Leverger, G, Locatelli, F, Masetti, R, Miyamura, T, Norén-Nyström, U, Polychronopoulou, S, Rasche, M, Rubnitz, J E, Stary, J, Tierens, A, Tomizawa, D, Zwaan, C M & Kaspers, G J L 2023, ' Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia : A Study by the International Berlin-Frankfurt-Münster Study Group ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 16, pp. 2963-2974 . https://doi.org/10.1200/JCO.22.02120
JOURNAL OF CLINICAL ONCOLOGY

PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged ( KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cccda2bbe5c51ff6074f87e156c5eb4a
http://www.scopus.com/inward/record.url?scp=85160455151&partnerID=8YFLogxK

Zobrazit plný text záznamu

Akademický článek

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy

Publikováno v: Haematologica, Vol 107, Iss 2 (2021)

Chemotherapy dosages are often compromised, but most reports lack data on dosages that are actually delivered. In two consecutive acute lymphoblastic leukemia trials that differed in their asparaginase formulation, native E. coli L-asparaginase in St

Externí odkaz: https://doaj.org/article/f2f424e701944bfb90237067ca32533f

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání